Anlotinib in combination with pembrolizumab for low-grade myofibroblastic sarcoma of the pancreas: A case report  

作　　者：Rong-Ting Wu Ji-Cheng Zhang Cheng-Nan Fang Xiao-Yu Qi Jin-Fei Qiao Ping Li Li Su 

机构地区：[1]Graduate School of Anhui University of Chinese Medicine,Anhui University of Chinese Medicine,Hefei 230022,Anhui Province,China [2]Department of Chinese Integrative Medicine Oncology,The First Affiliated Hospital of Anhui Medical University,Hefei 230022,Anhui Province,China [3]Oncology and General Practice,Suzhou Hospital of Traditional Chinese Medicine,Suzhou 234000,Anhui Province,China [4]The First Clinical College of Anhui Medical University,Anhui Medical University,Hefei 230022,Anhui Province,China

出　　处：《World Journal of Clinical Cases》2023年第35期8385-8391,共7页世界临床病例杂志

摘　　要：BACKGROUND Low-grade myofibroblastic sarcoma(LGMS)is a rare spindle cell sarcoma espe-cially in the pancreas,with myofibroblastic differentiation.Hitherto,only a few cases have been reported.CASE SUMMARY Herein,we report a case involving the discovery of a pancreatic mass detected during a routine physical examination.Subsequent imaging and pathological tests of the patient led to the diagnosis of LGMS of the pancreas.Following surgical intervention,the patient experienced recurrence and metastasis.Conventional treatment is not effective for postoperative recurrent pancreatic LGMS with multiple metastases.After communicating with the patients and their families,informed consent was obtained for the treatment of anlotinib combined with pembrolizumab.Evaluation of imaging and clinical symptoms post-treatment revealed a relatively favorable response to the combination of anlotinib and pembrolizumab.CONCLUSION Based on the comprehensive literature review,our report aimed to provide evidence for a better understanding of the disease characteristics,diagnostic criteria,imaging findings,and identification of LGMS.And explore novel treatment strategies for this disease.

关 键 词：Low-grade myofibroblastic sarcoma PANCREAS Pembrolizumab Anlotinib IMMUNOHISTOCHEMISTRY PATHOLOGY Case report 

分 类 号：R735.9[医药卫生—肿瘤]